在接受纳武单抗治疗的肾癌患者队列中，血红蛋白/红细胞分布宽度比的预后价值

Q3 Medicine

Cancer treatment and research communications Pub Date : 2025-01-01 DOI:10.1016/j.ctarc.2025.100927

Giulia Claire Giudice , Sara Elena Rebuzzi , Giulia Mazzaschi , Federica Pecci , Michele Maffezzoli , Alessandro Acunzo , Letizia Gnetti , Enrico Maria Silini , Giuseppe Caruso , Elena Rapacchi , Pasquale Rescigno , Giuseppe Fornarini , Giuseppe Luigi Banna , Sebastiano Buti

{"title":"在接受纳武单抗治疗的肾癌患者队列中，血红蛋白/红细胞分布宽度比的预后价值","authors":"Giulia Claire Giudice , Sara Elena Rebuzzi , Giulia Mazzaschi , Federica Pecci , Michele Maffezzoli , Alessandro Acunzo , Letizia Gnetti , Enrico Maria Silini , Giuseppe Caruso , Elena Rapacchi , Pasquale Rescigno , Giuseppe Fornarini , Giuseppe Luigi Banna , Sebastiano Buti","doi":"10.1016/j.ctarc.2025.100927","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab.</div></div><div><h3>Material and methods</h3><div>This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS).</div></div><div><h3>Results</h3><div>356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4–29.0) and 5.6 months (95 %CI 4.74.–7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS (<em>p</em> < 0.001) and PFS (<em>p</em> = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS.</div></div><div><h3>Conclusions</h3><div>The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100927"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab\",\"authors\":\"Giulia Claire Giudice , Sara Elena Rebuzzi , Giulia Mazzaschi , Federica Pecci , Michele Maffezzoli , Alessandro Acunzo , Letizia Gnetti , Enrico Maria Silini , Giuseppe Caruso , Elena Rapacchi , Pasquale Rescigno , Giuseppe Fornarini , Giuseppe Luigi Banna , Sebastiano Buti\",\"doi\":\"10.1016/j.ctarc.2025.100927\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab.</div></div><div><h3>Material and methods</h3><div>This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS).</div></div><div><h3>Results</h3><div>356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4–29.0) and 5.6 months (95 %CI 4.74.–7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS (<em>p</em> < 0.001) and PFS (<em>p</em> = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS.</div></div><div><h3>Conclusions</h3><div>The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.</div></div>\",\"PeriodicalId\":9507,\"journal\":{\"name\":\"Cancer treatment and research communications\",\"volume\":\"43 \",\"pages\":\"Article 100927\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment and research communications\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468294225000644\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294225000644","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

背景转移性肾细胞癌（mRCC）预后不佳。需要有效的预后和预测因素。血红蛋白(Hb) /红细胞分布宽度（RDW）比值越高，预后越好。在这里，我们评估了接受纳武单抗治疗的mRCC患者的Hb/RDW比率的预后价值。材料和方法：这是回顾性Meet-URO 15研究的亚分析，该研究针对接受纳武单抗治疗的mRCC患者。第一个目标是研究Hb/RDW比率在总生存期（OS）和无进展生存期（PFS）方面的预后作用。结果356例纳入分析。患者以男性为主，中位年龄63岁。我们根据两种不同的截断值将患者分为高和低Hb/RDW比率：文献中常用的截断值为0.9，时间依赖性AUC分析结果为0.7。中位OS和PFS分别为22.3个月（95% CI 19.4-29.0）和5.6个月（95% CI 4.74 - 7.53）。在单变量分析中，Hb/RDW比值越高，OS越长(p <；0.001)和PFS (p = 0.011)；多变量模型仅证实Hb/RDW比值≥0.7与较好的OS之间存在关联。结论Hb/RDW比值是一种易于管理和实用的癌症患者预后工具；在接受纳武单抗治疗的mRCC患者中，仅使用来自时间依赖性AUC的截止值，证实了其对OS的预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab

Background

Metastatic renal cell carcinoma (mRCC) has a dismal prognosis. Effective prognostic and predictive factors are needed. A higher haemoglobin (Hb) / red cell distribution width (RDW) ratio is known to be related to better outcomes. Here we evaluated the prognostic value of the Hb/RDW ratio in pre-treated mRCC patients receiving nivolumab.

Material and methods

This is a sub-analysis of the retrospective Meet-URO 15 study, on pre-treated patients with mRCC, receiving nivolumab. The first objective was to investigate the prognostic role of Hb/RDW ratio, in terms of overall survival (OS) and progression-free survival (PFS).

Results

356 were included in the present analysis. Patients were mainly males with a median age of 63 years. We classified patients in high and low Hb/RDW ratio, according to two different cut-offs: 0.9frequently used in literature, and 0.7, result of the time-dependent AUC analysis.. Median OS and PFS were 22.3 months (95 %CI 19.4–29.0) and 5.6 months (95 %CI 4.74.–7.53), respectively. At univariable analysis, higher Hb/RDW ratio was related to longer OS (p < 0.001) and PFS (p = 0.011); the multivariable model confirmed only the association between a Hb/RDW ratio ≥ 0.7 and better OS.

Conclusions

The Hb/RDW ratio is a manageable and practical prognostic tool in patients with cancer; its prognostic value for OS was confirmed in pre-treated mRCC patients, receiving nivolumab, only using a cut-off value derived from a time-dependent AUC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.